We love to hear from our listeners. Send us a message.
Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.
Subscribe to the podcast!Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
Cell & Gene: The Podcast